Melanoma Clinical Trial
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Summary
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Eligibility Criteria
Inclusion Criteria:
At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age
Completely removed melanoma by surgery performed within 12 weeks of randomization
Stage IIIb/C or Stage IV before complete resection
No previous anti-cancer treatment
Exclusion Criteria:
Ocular or uveal melanoma
History of carcinomatosis meningitis
History of auto-immune disease
Treatment directed against the resected melanoma that is administrated after the surgery
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
How clear is this clinincal trial information?